Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors

Cancer

Volumn 109, Issue 8, 2007, Pages 1638-1645

  Bozzi, Fabio ^a   Tamborini, Elena ^a   Negri, Tiziana ^a   Pastore, Elisa ^a   Ferrari, Andrea ^a   Luksch, Roberto ^a   Casanova, Michela ^a   Pierotti, Marco A ^a   Bellani, Franca Fossati ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Ewing sarcoma; KIT; PDGFR ; PDGFR ; RTK activation profile

Indexed keywords

ANTINEOPLASTIC AGENT; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ADOLESCENT; ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; CANCER PATIENT; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EWING SARCOMA; GENE TRANSLOCATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; RNA EXTRACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADOLESCENT; BLOTTING, WESTERN; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; POLYMERASE CHAIN REACTION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, EWING'S; STEM CELL FACTOR;

EID: 34247098863     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22587     Document Type: Article

References (22)

1. Hasegawa SL, Davison JM, Rutten A, Fletcher JA, Fletcher CDM. Primary cutaneous Ewing's sarcoma. Am J Surg Pathol. 1998;22:310-318.
2. Khoury JD. Ewing sarcoma family tumors. Adv Anat Pathol. 2005;12:212-220.
3. Ricotti E, Fagioli F, Garelli E et al. c-kit is expressed in soft tissue sarcoma of neuroectodermal origin and its ligand prevents apoptosis of neoplastic cells. Blood. 1998;91:2397-2405.
4. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst. 2002;94:1673-1679.
5. Tamborini E, Bonadiman L, Albertini V, Pierotti MA, Pilotti S. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst. 2003;95:1087-1088.
6. Scotlandi K, Manara MC, Strammiello R, et al. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol. 2003;21:1952-1960.
7. Uren A, Merchant MS, Sun CJ, et al. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene. 2003;22:2334-2342.
8. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003;30:4769-4784.
9. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162-165.
10. Lagonigro MS, Tamborini E, Negri T, et al. PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma. J Pathol. 2006;208:615-623.
11. Perrone F, Tamborini E, Dagrada P, et al. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer. 2005;104:159-169.
12. Winer J, Jung CK, Shackel I, et al. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999;270:41-49.
13. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer. 2004;101:2086-2097.
14. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib. Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866-873.
15. Huang HY, Illei PB, Zhao Z, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol. 2005;23:548-558.
16. Gonzalez I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res. 2004;10:751-761.
17. Picariello L, Sala SC, Martineti V, et al. A comparison of methods for the analysis of low abundance proteins in desmoid tumor cells. Anal Biochem. 2006;354:205-212.
18. Te Kronnie G, Timeus F, Rinaldi A, et al. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. Int J Mol Med. 2004;3:373-382.
19. Greco A, Roccato E, Mirando C, Cleris L, Formelli F, Pierotti MA. Growth-inhibitory effect of STI751 on cells tranformed by the COL1A1/PDGFB rearrangements. Int J Cancer. 2001;92:354-360.
20. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol. 2004;31(2 Suppl 6):18-23.
21. Chugh R, Thomas D, Wathen K, et al. Imatinib mesylate in soft tissue and bone sarcomas: interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. ASCO. 2004;23:814.
22. Negri T, Casieri P, Miselli F, et al. Evidence for PDGFRA, PDGFRB and KIT deregulation in NSCLC patient. Br J Cancer. 2007;96:180-181.